UK markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
883.20-7.48 (-0.84%)
At close: 04:00PM EDT
881.21 -1.99 (-0.23%)
After hours: 04:36PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close890.68
Open881.72
Bid881.96 x 100
Ask883.38 x 100
Day's range875.22 - 887.48
52-week range684.81 - 998.33
Volume502,941
Avg. volume466,462
Market cap96.942B
Beta (5Y monthly)0.14
PE ratio (TTM)25.42
EPS (TTM)34.74
Earnings date02 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est1,051.33
  • Zacks

    EXEL vs. REGN: Which Stock Is the Better Value Option?

    EXEL vs. REGN: Which Stock Is the Better Value Option?

  • Zacks

    Regeneron (REGN) Reports Next Week: What You Should Expect

    Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Reuters

    UPDATE 1-AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study

    AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to-head study. Rinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a no-to-little itch after 16 weeks of treatment, compared with 8.9% of patients treated with Dupixent, the study showed. The study is the first head-to-head trial in adults and adolescents with moderate-to-severe atopic dermatitis and had shown an inadequate response to systemic therapy, AbbVie said.